The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...
TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunothe ...
Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results